Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Michiel Strijbos, MD, GasthuisZusters Antwerpen, Antwerp, Belgium, discusses updates in genitourinary cancers to look forward to at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France, including data on the use of adjuvant ipilimumab and nivolumab in localized kidney cancer which may prove to be practice changing. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.